drugset / Trial / NCT00542425

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

NCT00542425

Phase 2 Completed 222 enrolled Radius Health, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether BA058 is effective in building bone in postmenopausal women with osteoporosis.

Timeline

Start
2007-04
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Abaloparatide Peptide 20 ug Subcutaneous
Subject Abaloparatide Peptide 40 ug Subcutaneous
Subject Abaloparatide Peptide 80 ug Subcutaneous
Comparator Teriparatide Protein / enzyme biologic 20 ug Subcutaneous

Indications